

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ruddy *et al.*

Serial No.: 08/852,495

Filed: May 7, 1997

For: POLYMORPHISMS IN THE  
REGION OF THE HUMAN  
HEMACHROMATOSIS GENE

Confirmation No.: 7064

Group Art Unit: 1634

Examiner: J. Goldberg

Attorney Docket No.: 8907-057-999

INFORMATION DISCLOSURE STATEMENTCommissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:
  - 1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.
  - 1b. A legible copy of :
    - ☒ Each U.S. patent application publication and U.S. and foreign patent;
    - ☒ Each publication or that portion which caused it to be listed on the PTO-1449;
    - ☐ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
    - ☐ all other information or portion which caused it to be listed on the PTO-1449.
  - 1c. ☐ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.
  - 1d. ☐ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.
2. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
  - ☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
  - ☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
  - ☒ Before the mailing of the first Office action on the merits;

- ☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.

3. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

*(Check either Item 3a or 3b)*

- 3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. ☐ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:  
☐ enclosed  
☐ to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

*(Item 3b to be checked if any reference known for more than 3 months)*

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- ☐ enclosed.  
☐ to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

The Certification Statement in Item 5 below is applicable.

5. ☐ Certification Statement (applicable if Item 3a or Item 4 is checked)

*(Check either Item 5a or 5b)*

- 5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- 5b. ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 5c. ☐ Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

6. ☐ This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

*(Check appropriate Items 6a, 6b and/or 6c)*

- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.

- 6b. ☐ Copies of publications listed on Form PTO-1449 from prior application Serial No. , filed on , of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c. ☐ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.
7. ☐ This is a Supplemental Information Disclosure Statement. (Check Item 7a)
- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .
8. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:
- ( Check Item 8a, 8b, or 8c)
- 8a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b. ☐ set forth in the application.
- 8c. ☐ enclosed as an attachment hereto.
9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Pennie & Edmonds LLP Deposit Account No. 16-1150.
10. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,




Nikolaos C. George, Reg. No. 39,201  
**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, N.Y. 10036-2711  
(212) 790-7900

Date: December 18, 2003

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



ATTY DOCKET NO.

8907-057-999

APPLICATION NO

08/852,495

APPLICANT

Ruddy et al.

FILING DATE

May 7, 1997

GROUP

1634

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,705,343	1/6/98	Drayna et al.			
	A02	5,712,098	1/27/98	Tsuchihashi et al.			
	A03	5,753,438	2/15/00	Drayna et al.			
	A04	6,140,305	10/31/00	Thomas et al.			
	A05	6,228,594	5/8/01	Thomas et al.			
	A06	6,284,732	9/4/01	Feder et al.			
	A07	6,391,852	5/21/02	Feder et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A08	WO 92/06180	4/16/92	PCT				
	A09	WO 93/14188	07/22/93	PCT				
	A10	WO 93/15609	08/19/93	PCT				
	A11	WO 93/19768	10/14/93	PCT				
	A12	WO 93/20221	10/14/93	PCT				
	A13	WO 94/06922	03/31/94	PCT				
	A14	WO 94/06923	03/31/94	PCT				

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	A15	Beutler, E. et al., "Mutation Analysis in Hereditary Hemochromatosis" <i>Blood Cells, Molecules, and Diseases</i> (1996), 22(16): 187-194
	A16	Gasparini, et al., "Where does the gene for Hemochromatosis lie in relation to HLA-A", <i>Hepatology</i> (1994), 19: 1050-1056.
	A17	Altman, J.D. et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," <i>Science</i> 274:94-96 (1996)
	A18	Anderson, G.J. et al., "Transferrin Receptor Distribution and Regulation in the Rat Small Intestine," <i>Gastroenterology</i> 98:576-585 (1990).
	A19	Arteaga, C.L. et al., "Tissue-targeted Antisense c-fos Retroviral Vector Inhibits Established Breast Cancer Xenografts in Nude Mice," <i>Canc. Res.</i> 56:10981103 (1996).
	A20	Banerjee, D. et al., "Transferrin Receptors in the Human Gastrointestinal Tract," <i>Gastroenterology</i> 91:861-869 (1986).
	A21	Brent, R. et al., "A bacterial repressor protein or a yeast transcriptional terminator can block upstream activation of a yeast gene," <i>Nature</i> 312:612-615 (1984).
	A22	Brent, R. et al., "A Eukaryotic Transcriptional Activator Bearing the DNA Specificity of a Prokaryotic Repressor," <i>Cell</i> 43:729-736 (1985).
	A23	Carbognani, P. et al., "Transferrin Receptor Expression in Nonsmall Cell Lung Cancer," <i>Cancer</i> 78(1):178-179 (1996).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.

8907-057-999

APPLICATION NO

08/852,495

APPLICANT

Ruddy et al.

FILING DATE

May 7, 1997

GROUP

1634

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

A24	Chien, C-T. <i>et al.</i> , "The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 88:9578-9582 (1991).
A25	Cook, J.D. <i>et al.</i> , "Serum Transferrin Receptor," <i>Annu. Rev. Med.</i> 44:63-74 (1993).
A26	Cox, G.A. <i>et al.</i> , "Overexpression of dystrophin in transgenic <i>mdx</i> mice eliminates dystrophic symptoms without toxicity," <i>Nature</i> 364:725-729 (1993).
A27	Curiel, D.T. <i>et al.</i> , "Adenovirus enhancement of transferrin-polylysine-mediated gene delivery," <i>FXoc. Natl. Acad. Sci. U.S.A.</i> 88:8850-8854 (1991).
A28	Dadone, M.M. <i>et al.</i> , "Hereditary Hemochromatosis. Analysis of Laboratory Expression of the Disease by Genotype in 18 Pedigrees," <i>Am. J. Clin. Pathol.</i> 78(2):196-207 (1982).
A29	Dalesandro, J. <i>et al.</i> , "Cardiac and Pulmonary Replacement," <i>J. Thoracic and Cardio. Surgery</i> 111(2):416-422 (1996).
A30	Delahunty, C. <i>et al.</i> , "Testing the Feasibility of DNA Typing for Human Identification by PCR and an Oligonucleotide Ligation Assay," <i>Am. J. Hum. Genet.</i> 58:1239-1246 (1996).
A31	Edwards, C.Q. <i>et al.</i> , "Prevalence of Hemochromatosis Among 11,065 Presumably Healthy Blood Donors," <i>N. Engl. J. Med.</i> 318(21):1355-1362 (1988).
A32	Fahnestock, M.L. <i>et al.</i> , "Thermal Stability Comparison of Purified Empty and Peptide-Filled Forms of a Class I MHC Molecule," <i>Science</i> 258:1658-1662 (1992).
A33	Fahnestock, M.L. <i>et al.</i> , "The MHC Class I Homolog Encoded by Human Cytomegalovirus Binds Endogenous Peptides," <i>Immunity</i> 3:583-590 (1995).
A34	Feder, J.N. <i>et al.</i> , "The Hemochromatosis Founder Mutation in HLA-H Disrupts $\beta_2$ - Microglobulin Interaction and Cell Surface Expression," <i>J. Biol. Chem.</i> 272(22):14025-14028 (1997).
A35	Friedman, J.M. <i>et al.</i> , "Cellular Promoters Incorporated into the Adenovirus Genome: Cell Specificity of Albumin and Immunoglobulin Expression," <i>Mol. Cell. Biol.</i> 6(11):3791-3797 (1986).
A36	Gastinel, L.N. <i>et al.</i> , "Expression and crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibility molecules," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89:638-642 (1992).
A37	Hatzoglou, M. <i>et al.</i> , "Hepatic Gene Transfer in Animals Using Retroviruses Containing the Promoter from the Gene for Phosphoenolpyruvate Carboxykinase," <i>J. Biol. Chem.</i> 265(28):17285-17293 (1990).
A38	Huber, B.E. <i>et al.</i> , "Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 88:8039-8043 (1991).
A39	Jahroudi, N. <i>et al.</i> , "Endothelial-Cell-Specific Regulation of von Willebrand Factor Gene Expression," <i>Mol. Cell. Biol.</i> 14(2):999-1008 (1994).
A40	Karin, M. <i>et al.</i> , "Receptor-mediated Endocytosis of Transferrin in Developmentally Totipotent Mouse Teratocarcinoma Stem Cells," <i>J. Biol. Chem.</i> 256(7):3245-3252 (1981).
A41	Keer, H.N. <i>et al.</i> , "Elevated Transferrin Receptor Content in Human Prostate Cancer Cell Lines Assessed In Vitro and In Vivo," <i>J. Urol.</i> , 143:381-385 (1990).
A42	Klausner, R.D. <i>et al.</i> , "Receptor-mediated Endocytosis of Transferrin in K562 Cells," <i>J. Biol. Chem.</i> 258:4715-4724 (1983).
A43	Koc, O.N. <i>et al.</i> , "Transfer of Drug Resistance Genes into Hematopoietic Progenitors to Improve Chemotherapy Tolerance," <i>Sem. Oncol.</i> 23(1):46-65 (1996).
A44	Letourneur, F. <i>et al.</i> , "A Novel Di-Leucine Motif and a Tyrosine-Based Motif Independently Mediated Lysosomal Targeting and Endocytosis of CD 3 Chains," <i>Cell</i> 69:1143-1157 (1992).
A45	Makarov, S.S., "Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 93:402406 (1996).
A46	Marks, M.S. <i>et al.</i> , "A Lysosomal Targeting Signal in the Cytoplasmic Tail of the (3 Chain Directs HLA-DM to MHC Class II Compartments," <i>J. Cell Biol.</i> 131:351-369 (1995).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.

8907-057-999

APPLICATION NO

08/852,495

APPLICANT

Ruddy et al.

FILING DATE

May 7, 1997

GROUP

1634

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

A47	Maxwell, I.H. <i>et al.</i> , "Expression of the Diphtheria Toxin A-Chain Coding Sequence under the Control of Promoters and Enhancers from Immunoglobulin Genes as a Means of Directing Toxicity of B-Lymphoid Cells," <i>Canc. Res.</i> 51:4299-4304 (1991).
A48	McClelland, A. <i>et al.</i> , "The Human Transferrin Receptor Gene: Genomic Organization, and the Complete Primary Structure of the Receptor Deduced from a cDNA Sequence," <i>Cell</i> 39:267-274 (1984).
A49	McLaren, C.E. <i>et al.</i> , "Prevalence of Heterozygotes for Hemochromatosis in the White Population of the United States," <i>Blood</i> 86(5):2021-2027 (1995).
A50	Miller, N. <i>et al.</i> , "Targeted vectors for gene therapy," <i>FASEB J.</i> 9:190-199 (1995).
A51	Miyazaki, J-I. <i>et al.</i> , "Expression vector system based on the chicken $\beta$ -actin promoter directs efficient production of interleukin-5," <i>Gene</i> 79:269-277 (1989).
A52	Nolta, J.A. <i>et al.</i> , "Transduction of: pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 93:2414-2419 (1996).
A53	Octave, J-N <i>et al.</i> , "Transferrin Uptake by Cultured Rat Embryo Fibroblasts," <i>Eur. J. Biochem.</i> 123:235-240 (1982).
A54	Oliveira, H.C.F. <i>et al.</i> , "Human Cholesteryl Ester Transfer Protein Gene Proximal Promoter Contains Dietary Cholesterol Positive Responsive Elements and Mediates Expression in Small Intestine and Periphery While Predominant Liver and Spleen Expression is Controlled by 5'-distal Sequences," <i>J. Biol. Chem.</i> 271(510):31831-31838 (1996).
A55	Omary, M.B. <i>et al.</i> , "Biosynthesis of the Human Transferrin Receptor in Cultured Cells," <i>J. Biol. Chem.</i> 256(24):12888-12892 (1981).
A56	Parham, P <i>et al.</i> , "Arginine 45 is a Major Part of the Antigenic Determinant of Human $\beta_2$ -Microglobulin Recognized by Mouse Monoclonal Antibody BBM.1," <i>J. Biol. Chem.</i> 258(10):6179-6186 (1983).
A57	Parkkila, S. <i>et al.</i> , "Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 94:2534-2539 (1997).
A58	Petrylak, D.P. <i>et al.</i> , "Transferrin Receptor Expression in Testis Cancer," <i>J. Natl. Canc. Inst.</i> 86(8):636-637 (1994).
A59	Plank, C. <i>et al.</i> , "The Influence of Endosome-disruptive Peptides on Gene Transfer Using Synthetic Virus-like Gene Transfer Systems," <i>J. Biol. Chem.</i> 269(17):12918-12924 (1994).
A60	Raghavan, M. <i>et al.</i> , "The Class I Major Histocompatibility Complex Related Fc Receptor Shows pH-Dependent Stability Differences Correlating with Immunoglobulin Binding and Release," <i>Biochemistry</i> 32:8654-8660 (1993).
A61	Raper, S.E. <i>et al.</i> , "Safety and Feasibility of Liver-Directed Ex Vivo Gene Therapy for Homozygous Familial Hypercholesterolemia," <i>Annal. of Surgery</i> 223 (2):116-126 (1996).
A62	Rotzschke, O. <i>et al.</i> , "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," <i>Nature</i> 348:252-254 (1990).
A63	Ruddy, D.A. <i>et al.</i> , "A 1.1-Mb Transcript Map of the Hereditary Hemochromatosis Locus," <i>Genome Res.</i> 7:441-456 (1997).
A64	Schaeffer, E. <i>et al.</i> , "Complete structure of the human transferrin gene. Comparison with analogous chicken gene and human pseudogene," <i>Gene</i> 56:109-116 (1987).
A65	Schneider, C. <i>et al.</i> , "Primary structure of human transferrin receptor deduced from the mRNA sequence," <i>Nature</i> 311:675-678 (1984).
A66	Seligman, P.A. <i>et al.</i> , "Isolation and Characterization of the Transferrin Receptor from Human Placenta," <i>J. Biol. Chem.</i> 254(20):9943-9946 (1979).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

8907-057-999

APPLICATION NO

08/852,495

APPLICANT

Ruddy et al.

FILING DATE

May 7, 1997

GROUP

1634

A67	Sugita, M. <i>et al.</i> , "Cytoplasmic Tail-Dependent Localization of CD1b Antigen-Presenting molecules to MHCs," <i>Science</i> 273:349-352 (1996).
A68	Uhlmann, E. <i>et al.</i> , "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chem. Rev.</i> 90(4):543-584 (1990).
A69	Vandewalle, B. <i>et al.</i> , "Transferrin Receptors in Cultured Breast Cancer Cells," <i>J. Canc. Res. Clin. Oncol.</i> 110:71-76 (1985).
A70	Voorhees, P. <i>et al.</i> , "An acidic sequence within the cytoplasmic domain of furin functions as a determinant of <i>trans</i> -Golgi network localization and internalization from the cell surface," <i>FMBO J.</i> 14(20):4961-4975 (1995).
A71	Wada, H.G. <i>et al.</i> , "Transferrin Receptor in Human Placental Brush Border Membranes," <i>J. Biol. Chem.</i> 254(24):12629-12635 (1979).
A72	Ward, J.H. <i>et al.</i> , "Regulation of HeLa Cell Transferrin Receptors," <i>J. Biol. Chem.</i> 257(17):10317-10323 (1982).
A73	Waugh, S.M. <i>et al.</i> , "Isolation of a :Proteolytically Derived Domain of the Insulin Receptor Containing the Major Site of Cross-Linking/Binding," <i>Biochemistry</i> 28:3448-3455 (1989).
A74	Weiser, P. <i>et al.</i> , "Endosomal Targeting by the Cytoplasmic Tail of Membrane Immunoglobulin," <i>Science</i> 276:407-409 (1997).
A75	Williams, M.A. <i>et al.</i> , "Accumulation of Membrane Glycoproteins in Lysosomes Requires a Tyrosine Residue at a Particular Position in the Cytoplasmic Tail," <i>J. Cell Biol.</i> 111:955-966 (1990).
A76	Wu, G.Y. <i>et al.</i> , "Receptor-mediated Gene Delivery and Expression in Vivo," <i>Biol. Chem.</i> 263(29):14621-14624 (1988).
A77	Zou, L. <i>et al.</i> , "Isolation of a Liver-Specific Promoter for Human Growth Hormone Receptor Gene," <i>Endocrin.</i> 138(4):1771-1774 (1997).
A78	Alvarez <i>et al.</i> , "Inhibition of the Receptor-Mediated Endocytosis of Diferric Transferrin Is Associated with the Covalent Modification of the Transferrin Receptor with Palmitic Acid" <i>JBC</i> (1990) 265(27):16644-16655.
A79	Alvarez <i>et al.</i> , "A Point Mutation In the Cytoplasmic Domain of the Transferrin Receptor Inhibits Endocytosis", <i>Biochem J.</i> (1990): 267: 31-35.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.